---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-369426"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2026-08-27T10:01:18+00:00"
generated_at: "2026-08-27T10:10:07.865855+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cyclerion shareholders approve merger proposals; 1-for-7 reverse split; redomestication fails

## Summary
- Shareholders approved Nasdaq issuance, authorized share increase to 700M, reverse split, and 2026 stock plans; redomestication to Cayman failed.
- Board set reverse split at 1-for-7, cutting shares from ~4.7M to ~0.7M; fractional shares paid in cash.
- Combined company to trade as Korsana Biosciences, Inc. (KRSA) on Nasdaq from Sept 9, 2026, with new CUSIP 23255M303.
- Redomestication failure not a condition to close; merger remains pending with closing conditions to be satisfied.

## SEC filing metadata
- accession: 0001193125-26-369426
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2026-08-27T10:01:18+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000119312526369426/0001193125-26-369426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000119312526369426/d264301d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-369426
- JSON: https://secwatch.observer/filing/0001193125-26-369426.json
- Plain text: https://secwatch.observer/filing/0001193125-26-369426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.